Hemolysis is the rupture of red blood cells, and it has multiple causes, can happen at any time, both in vivo and in vitro. Hemolysis Can Endanger Your Results Hemolysis can certainly impact study results, and has a particularly well-documented impact on potassium concentration measurements.
The Benefits and Challenges of Real-World Data to Support Traditional Clinical Trial Initiatives Historically, medical research data obtained from other sources outside of traditional clinical trials were viewed with a heavy dose of skepticism even before evaluation of the methodology. Although this real-world data (RWD) was widely used to satisfy safety monitoring and post-drug approval regulation requirements, many clinicians viewed RWD and the real-world evidence (RWE) it generated as unverified and unreliable data mining explorations with drug marketing objectives.
Study-patient recruitment and retention continue to be significant challenges in medical research. According to a Tufts Center for the Study of Drug Development report, 48% of study sites miss their enrollment targets, and 11% fail to enroll a single patient. This results in the need for study sponsors to nearly double study timelines to meet recruitment goals.
The coronavirus pandemic has altered virtually every aspect of life. Pharmaceutical research, specifically clinical trials, are no exception. To slow the virus’ spread, the Centers for Disease Control and Prevention has recommended social distancing — essentially, avoiding close contact with others.
The at-home isolation and social distancing orders for millions of Americans is a vital element to slow to the COVID-19 pandemic. With most of our daily activities on-hold or modified for the foreseeable future, medical research is a crucial pursuit that continues despite the current environment.
Considerations for Feasibility for Translational Research For many researchers, considering the feasibility of a translational study with Sanguine Biosciences is a crucial yet challenging step. The proposed study they submit might not be possible based on real-world evidence or Sanguine’s service offerings, requiring them to modify their criteria.
The global search for a treatment targeting the novel coronavirus has led to an unlikely potential savior: a cocoa-colored llama named Winter, whose blood could hold a weapon to blunt the virus. She lives at a research farm in Belgium with about 130 other llamas and alpacas.
Systemic lupus erythematosus (SLE), also known as lupus, is a chronic autoimmune disease caused by random or inherited mutations in various genes of the immune system. It affects the skin, joints, kidneys, brain, and almost every other organ. People suffering from SLE experience inflammation in the connective tissues that provide strength and flexibility to structures throughout the body.
WBZ | CBS Boston – Lara Woolfson’s COVID-19 story and her participation with Sanguine for her in-home blood sample collection. Transcript: Headline News: Live from the Channel 4 Studios in Boston, this is WBZ news at 5:30. Liam Martin: Well for a photographer from Boston who has already recovered from the coronavirus is hoping that her fight with it will help others recover as well.
One of the challenges to securing the participation of patients in clinical trials can be simple geography. Sanguine Biosciences is seeking to tear down that barrier to participation by using mobile technology to bring clinical trials to patients. The company recently partnered with Vir Biotechnology to complete a COVID-19 clinical study aimed at better understanding the biology of the disease by sending healthcare personnel to collect blood samples from patients at their homes.